1) our results will be for VD vascular dimentia only,... will they be interpreted by investors as good for Alzheimers also,...?
2) our trial uses the Montreal Cognition test (my home town), whereas the Biogen Alzheimers drug used another test,.... will we be able to compare the 2 test results,...?